Veru Inc (NASDAQ:VERU) shares are trading significantly higher Monday after the company reported its novel COVID-19 drug candidate reduced deaths by 55% in hospitalized patients in an interim analysis of the Phase 3 study.
The study evaluated the company's oral COVID-19 candidate sabizabulin versus placebo in 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome.
